Latest & greatest articles for asthma

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on asthma or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on asthma and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for asthma

101. Early Probiotic Supplementation for Eczema and Asthma Prevention: A Randomized Controlled Trial

Early Probiotic Supplementation for Eczema and Asthma Prevention: A Randomized Controlled Trial 28784701 2017 08 08 2017 09 15 2017 10 15 1098-4275 140 3 2017 Sep Pediatrics Pediatrics Early Probiotic Supplementation for Eczema and Asthma Prevention: A Randomized Controlled Trial. e20163000 10.1542/peds.2016-3000 To determine if probiotic administration during the first 6 months of life decreases childhood asthma and eczema. We conducted a randomized, double-blind controlled trial (...) of Lactobacillus rhamnosus GG (LGG) supplementation on the cumulative incidence of eczema (primary end point) and asthma and rhinitis (secondary end points) in high-risk infants. For the first 6 months of life, intervention infants (n = 92) received a daily dose of 10 billion colony-forming units of LGG and 225 mg of inulin (Amerifit Brands, Cromwell, CT), and control infants (n = 92) received 325 mg of inulin alone. We used survival analysis methods to estimate disease incidences in the presence or absence

Full Text available with Trip Pro

2017 EvidenceUpdates

102. A Roadmap for Optimizing Asthma Care Management via Computational Approaches (PubMed)

A Roadmap for Optimizing Asthma Care Management via Computational Approaches 28951380 2018 11 13 2291-9694 5 3 2017 Sep 26 JMIR medical informatics JMIR Med Inform A Roadmap for Optimizing Asthma Care Management via Computational Approaches. e32 10.2196/medinform.8076 Asthma affects 9% of Americans and incurs US $56 billion in cost, 439,000 hospitalizations, and 1.8 million emergency room visits annually. A small fraction of asthma patients with high vulnerabilities, severe disease, or great (...) . 2013 Oct;19(5):727-33 21410844 J Gen Intern Med. 2007 Dec;22 Suppl 3:391-5 18026807 J Clin Epidemiol. 2015 Jan;68(1):25-34 25441703 Dis Manag. 2005 Oct;8(5):277-87 16212513 J Asthma. 1999 Jun;36(4):359-70 10386500 Health Aff (Millwood). 2015 Jun;34(6):993-1000 26056205 Am J Manag Care. 2013 Jan;19(1):60-7 23379745 Health Aff (Millwood). 2014 Jan;33(1):124-31 24395944 CMAJ. 2013 Jul 9;185(10):E499-505 23339155 Yearb Med Inform. 2016 May 20;Suppl 1:S48-61 27199197 Medicine (Baltimore). 2015 Aug;94(31

Full Text available with Trip Pro

2017 JMIR medical informatics

103. Asthma-COPD overlap syndrome: pathogenesis, clinical features, and therapeutic targets. (PubMed)

Asthma-COPD overlap syndrome: pathogenesis, clinical features, and therapeutic targets. Asthma-COPD overlap syndrome (ACOS) or asthma-COPD overlap captures the subset of patients with airways disease who have features of both asthma and chronic obstructive pulmonary disease (COPD). Although definitions of ACOS vary, it is generally thought to encompass persistent airflow limitation in a patient older than 40 years of age with either a history of asthma or large bronchodilator reversibility (...) . ACOS affects about a quarter of patients with COPD and almost a third of patients who previously had asthma. Compared with their counterparts with asthma or COPD alone, patients with ACOS have significantly worse respiratory symptoms, poorer quality of life, and increased risk of exacerbations and hospital admissions. Whether this condition emerges after gradual shifts in airway remodelling and inflammation in a patient with COPD, as the result of noxious exposures in a patient with asthma, or even

2017 BMJ

104. Effectiveness of fluticasone furoate plus vilanterol on asthma control in clinical practice: an open-label, parallel group, randomised controlled trial. (PubMed)

Effectiveness of fluticasone furoate plus vilanterol on asthma control in clinical practice: an open-label, parallel group, randomised controlled trial. BACKGROUND: Evidence for management of asthma comes from closely monitored efficacy trials done in highly selected patient groups. There is a need for randomised trials that are closer to usual clinical practice. METHODS: We did an open-label, randomised, controlled, two-arm effectiveness trial at 74 general practice clinics in Salford (...) and South Manchester, UK. Patients aged 18 years or older with a general practitioner's diagnosis of symptomatic asthma and on maintenance inhaler therapy were randomly assigned to initiate treatment with a once-daily inhaled combination of either 100 μg or 200 μg fluticasone furoate with 25 μg vilanterol or optimised usual care and followed up for 12 months. The primary endpoint was the percentage of patients who achieved an asthma control test (ACT) score of 20 or greater or an increase in ACT score

Full Text available with Trip Pro

2017 Lancet

105. Tezepelumab in Adults with Uncontrolled Asthma. (PubMed)

Tezepelumab in Adults with Uncontrolled Asthma. BACKGROUND: In some patients with moderate-to-severe asthma, particularly those with noneosinophilic inflammation, the disease remains uncontrolled. This trial evaluated the efficacy and safety of tezepelumab (AMG 157/MEDI9929), a human monoclonal antibody specific for the epithelial-cell-derived cytokine thymic stromal lymphopoietin (TSLP), in patients whose asthma remained uncontrolled despite treatment with long-acting beta-agonists and medium (...) -to-high doses of inhaled glucocorticoids. METHODS: In this phase 2, randomized, double-blind, placebo-controlled trial, we compared subcutaneous tezepelumab at three dose levels with placebo over a 52-week treatment period. The primary end point was the annualized rate of asthma exacerbations (events per patient-year) at week 52. RESULTS: The use of tezepelumab at a dose of 70 mg every 4 weeks (low dose; 145 patients), 210 mg every 4 weeks (medium dose; 145 patients), or 280 mg every 2 weeks (high

2017 NEJM

106. The Relationship between Caesarean Delivery and Increased Risk of Developing Asthma in Childhood

The Relationship between Caesarean Delivery and Increased Risk of Developing Asthma in Childhood "The Relationship between Caesarean Delivery and Increased Risk of Deve" by Nicole Ankenbrandt > > > > > Title Author Date of Graduation Summer 8-12-2017 Degree Type Thesis Degree Name Master of Science in Physician Assistant Studies Rights . Abstract Background: Asthma prevalence nationwide is increasing. In 2011, an estimated 39.5 million individuals, or 12.9% of the population, had a diagnosis (...) of asthma, and 14% of those were children. Rate of caesarean delivery (CD) has concurrently increased over the past few decades and comprised 32.2% of all deliveries in 2014. Recent research has begun to explore for possible association between CD and later asthma development. Studies may even suggest differences in the gastrointestinal microbiome of neonates after CD and that of neonates after vaginal delivery (VD); this microbiome has been shown to affect development of a properly functioning immune

2017 Pacific University EBM Capstone Project

107. Asthma

Asthma Prodigy Toggle navigation Topics Specialities A B C D E F G H I J K L M N O P Q R S T U V W X Y Z Allergies Cancer Cardiovascular Child health Drugs and devices Ear, nose and throat Endocrine and metabolic Eyes Gastrointestinal Haematology Immunizations Infections and infestations Injuries Kidney disease and urology Men's health Mental health Musculoskeletal Neurological Oral health Palliative care Poisoning Pregnancy Preventative medicine Respiratory Sexual health Skin and nail Women's (...) health Asthma - Topic Menu Asthma: Summary Asthma is a chronic inflammatory condition of the airways. The airways are hyper-responsive and constrict easily in response to a wide range of stimuli. This may result in coughing, wheezing, chest tightness, and shortness of breath. Narrowing of the airways is usually reversible (either spontaneously or with medication), leading to intermittent symptoms, but in some people with chronic asthma, the inflammation may lead to irreversible airflow obstruction

2017 Prodigy

108. [Reslizumab (asthma) - addendum to Commission A17-02]

[Reslizumab (asthma) - addendum to Commission A17-02] Reslizumab (Asthma): addendum zum auftrag A17-02; auftrag A17-22 [Reslizumab (asthma) - addendum to Commission A17-02] Reslizumab (Asthma): addendum zum auftrag A17-02; auftrag A17-22 [Reslizumab (asthma) - addendum to Commission A17-02] Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality (...) of this assessment has been made for the HTA database. Citation Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Reslizumab (Asthma): addendum zum auftrag A17-02; auftrag A17-22. [Reslizumab (asthma) - addendum to Commission A17-02] Cologne: Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). IQWiG-Berichte 516. 2017 Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Anti-Asthmatic Agents; Antibodies, Monoclonal, Humanized; Asthma; Humans

2017 Health Technology Assessment (HTA) Database.

109. Acarizax - house dust mite allergic rhinitis and allergic asthma

Acarizax - house dust mite allergic rhinitis and allergic asthma Acarizax® × Insert searchphrase to search the website Insert searchphrase to search the website > > > Acarizax® Conclusion It is IRF's overall assessment that Acarizax may be considered a relevant add-on therapy in house dust mite allergic rhinitis and allergic asthma in adults when symptomatic treatment is not adequate. Immunotherapy is a long-term treatment form, requiring high patient motivation, and after treatment

2017 Danish Pharmacotherapy Reviews

110. Rapid vs Maintenance Vitamin D Supplementation in Deficient Children With Asthma to Prevent Exacerbations

Rapid vs Maintenance Vitamin D Supplementation in Deficient Children With Asthma to Prevent Exacerbations 28651793 2017 06 27 2017 09 22 2017 09 22 1931-3543 152 3 2017 Sep Chest Chest Rapid vs Maintenance Vitamin D Supplementation in Deficient Children With Asthma to Prevent Exacerbations. 527-536 S0012-3692(17)31178-9 10.1016/j.chest.2017.06.021 Whether vitamin D reduces clinically important exacerbations of childhood asthma remains uncertain. We compared rapid to maintenance vitamin D (...) repletion analyzed by baseline vitamin D level. Children presenting to the ED with moderate-to-severe asthma exacerbations and vitamin D levels ≤ 25 ng/mL underwent masked randomization, and then open dosing to either IM+oral (the latter daily) therapy or daily oral-only therapy, and were followed for 12 months. The primary outcome was patient-initiated unplanned visits for asthma exacerbations, examined two ways: cumulative proportions with an exacerbation, and average exacerbation frequency

2017 EvidenceUpdates

111. Stratification of eosinophilic asthma patients treated with reslizumab and GINA Step 4 or 5 therapy (PubMed)

Stratification of eosinophilic asthma patients treated with reslizumab and GINA Step 4 or 5 therapy 28845430 2018 11 13 2312-0541 3 3 2017 Jul ERJ open research ERJ Open Res Stratification of eosinophilic asthma patients treated with reslizumab and GINA Step 4 or 5 therapy. 00004-2017 10.1183/23120541.00004-2017 Reslizumab, an anti-interleukin-5 monoclonal antibody, significantly reduces exacerbation frequency and improves lung function, asthma control and quality of life in adults with severe (...) eosinophilic asthma, as demonstrated in Phase III studies. This secondary analysis assessed reslizumab's efficacy in patients receiving baseline treatment per Global Initiative for Asthma (GINA) Step 4 and Step 5 guidelines. Pooled data from duplicate, Phase III, reslizumab versus placebo studies in patients with severe eosinophilic asthma (blood eosinophils ≥400 cells·µL -1 ) were stratified by baseline therapy. Efficacy assessments were exacerbation rates and changes from baseline forced

Full Text available with Trip Pro

2017 ERJ open research

112. Trends in international asthma mortality: analysis of data from the WHO Mortality Database from 46 countries (1993-2012). (PubMed)

Trends in international asthma mortality: analysis of data from the WHO Mortality Database from 46 countries (1993-2012). BACKGROUND: International time trends in asthma mortality have been strongly affected by changes in management and in particular drug treatments. However, little is known about how asthma mortality has changed over the past decade. In this study, we assessed these international trends. METHODS: We collated age-standardised country-specific asthma mortality rates in the 5-34 (...) year age group from the online WHO Mortality Database for 46 countries. To be included in the analysis, we specified that a country must have 10 years of complete data in the WHO Mortality Database between 1993 and 2012. In the absence of consistent and accurate asthma prevalence and prescribing data, we chose to use a locally weighted scatter plot smoother (LOESS) curve, weighted by the individual country population in the 5-34-year age group to show the global trends in asthma mortality rates

2017 Lancet

113. Omega-3 fatty acids during pregnancy and asthma prevention. Are we talking here about more than just a suspect involved?

Omega-3 fatty acids during pregnancy and asthma prevention. Are we talking here about more than just a suspect involved? Evidencias en pediatría - Ácidos grasos omega-3 durante el embarazo y prevención del asma, ¿algo más que un presunto implicado? Buscando, por favor espere. Mostrar menú Gestión de biblioteca Aún no ha añadido ningún artículo a su biblioteca. | Buscar Toma de decisiones clínicas basadas en pruebas científicas Toma de decisiones clínicas basadas en pruebas científicas Mostrar (...) mujeres en la semana 22-26 de embarazo para realizar el ensayo clínico. Los hijos de estas mujeres forman parte de la cohorte de Copenhagen Prospective Studies on Asthma in Chilhood 2010 (COPSAC2010). Las mujeres rellenaron un cuestionario de frecuencias de consumo de alimentos y se midieron sus niveles de ácido eicosapentaenoico (EPA) y docosahexaenoico (DHA) antes de la aleatorización y una semana después del parto. Tras el parto, la cohorte se formó con 695 niños, de los que el 95,5% completaron el

2017 Evidencias en Pediatría

114. Reslizumab (severe eosinophilic asthma) ? Benefit assessment according to § 35a Social Code Book V

Reslizumab (severe eosinophilic asthma) ? Benefit assessment according to § 35a Social Code Book V Extract 1 Translation of Sections 2.1 to 2.6 of the dossier assessment Reslizumab (Asthma) – Nutzenbewertung gemäß § 35a SGB V (Version 1.0; Status: 11 April 2017). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. IQWiG Reports – Commission No. A17-02 Reslizumab (...) (asthma) – Benefit assessment according to §35a Social Code Book V 1 Extract of dossier assessment A17-02 Version 1.0 Reslizumab (asthma) 11 April 2017 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Reslizumab (asthma) – Benefit assessment according to §35a Social Code Book V Commissioning agency: Federal Joint Committee Commission awarded on: 16 January 2017 Internal Commission No.: A17-02

2017 Institute for Quality and Efficiency in Healthcare (IQWiG)

115. Preventing Severe Asthma Exacerbations in Children. A Randomized Trial of Mite-Impermeable Bedcovers

Preventing Severe Asthma Exacerbations in Children. A Randomized Trial of Mite-Impermeable Bedcovers 28282501 2017 03 10 2017 07 31 2017 07 31 1535-4970 196 2 2017 Jul 15 American journal of respiratory and critical care medicine Am. J. Respir. Crit. Care Med. Preventing Severe Asthma Exacerbations in Children. A Randomized Trial of Mite-Impermeable Bedcovers. 150-158 10.1164/rccm.201609-1966OC Allergen exposure in sensitized individuals with asthma interacts with viruses to increase the risk (...) of asthma exacerbation. To evaluate the use of house dust mite-impermeable bedding and its impact on severe asthma exacerbations in children. We randomized mite-sensitized children with asthma (ages 3-17 yr) after an emergency hospital attendance with an asthma exacerbation to receive mite-impermeable (active group) or control (placebo group) bed encasings. Over a 12-month intervention period, the occurrence of severe asthma exacerbations was investigated. Of 434 children with asthma who consented, 286

Full Text available with Trip Pro

2017 EvidenceUpdates

117. Diagnosis and Management of Asthma in Adults: A Review. (PubMed)

Diagnosis and Management of Asthma in Adults: A Review. Importance: Asthma affects about 7.5% of the adult population. Evidence-based diagnosis, monitoring, and treatment can improve functioning and quality of life in adult patients with asthma. Observations: Asthma is a heterogeneous clinical syndrome primarily affecting the lower respiratory tract, characterized by episodic or persistent symptoms of wheezing, dyspnea, and cough. The diagnosis of asthma requires these symptoms (...) and demonstration of reversible airway obstruction using spirometry. Identifying clinically important allergen sensitivities is useful. Inhaled short-acting β2-agonists provide rapid relief of acute symptoms, but maintenance with daily inhaled corticosteroids is the standard of care for persistent asthma. Combination therapy, including inhaled corticosteroids and long-acting β2-agonists, is effective in patients for whom inhaled corticosteroids alone are insufficient. The use of inhaled long-acting β2-agonists

2017 JAMA

118. Effect of azithromycin on asthma exacerbations and quality of life in adults with persistent uncontrolled asthma (AMAZES): a randomised, double-blind, placebo-controlled trial. (PubMed)

Effect of azithromycin on asthma exacerbations and quality of life in adults with persistent uncontrolled asthma (AMAZES): a randomised, double-blind, placebo-controlled trial. BACKGROUND: Exacerbations of asthma cause a substantial global illness burden. Adults with uncontrolled persistent asthma despite maintenance treatment require additional therapy. Since macrolide antibiotics can be used to treat persistent asthma, we aimed to assess the efficacy and safety of oral azithromycin as add (...) -on therapy in patients with uncontrolled persistent asthma on medium-to-high dose inhaled corticosteroids plus a long-acting bronchodilator. METHODS: We did a randomised, double-blind, placebo controlled parallel group trial to determine whether oral azithromycin decreases the frequency of asthma exacerbations in adults (≥18 years) with symptomatic asthma despite current use of inhaled corticosteroid and long-acting bronchodilator, and who had no hearing impairment or abnormal prolongation

2017 Lancet

119. Variations in the prevalence of childhood asthma and wheeze in MeDALL cohorts in Europe (PubMed)

Variations in the prevalence of childhood asthma and wheeze in MeDALL cohorts in Europe 28845428 2018 11 13 2312-0541 3 3 2017 Jul ERJ open research ERJ Open Res Variations in the prevalence of childhood asthma and wheeze in MeDALL cohorts in Europe. 00150-2016 10.1183/23120541.00150-2016 While there is evidence for variations in prevalence rates of childhood wheeze and asthma between countries, longitudinal, individual-level data are needed to understand these differences. The aim (...) of this study was to examine variations in prevalence rates of childhood asthma, wheeze and wheeze with asthma in Europe. We analysed datasets from 10 MeDALL (Mechanisms of the Development of ALLergy) cohorts in eight countries, representing 26 663 children, to calculate prevalence rates of wheeze and asthma by child age and wheeze with asthma at age 4 years. Harmonised variables included outcomes parent-reported wheeze and parent-reported doctor-diagnosed asthma, and covariates maternal education, parental

Full Text available with Trip Pro

2017 ERJ open research

120. An evidence-based, point-of-care tool to guide completion of asthma action plans in practice (PubMed)

An evidence-based, point-of-care tool to guide completion of asthma action plans in practice 28461295 2017 05 02 2017 06 11 1399-3003 49 5 2017 May The European respiratory journal Eur. Respir. J. An evidence-based, point-of-care tool to guide completion of asthma action plans in practice. 1602238 10.1183/13993003.02238-2016 Asthma action plans (AAPs) reduce healthcare utilisation, improve quality of life and are recommended across guidelines. However, fewer than 25% of patients receive an AAP (...) , partly due to prescribers' inability to complete "yellow zone" instructions (how to intensify therapy for acute loss of control). We sought to review best evidence to develop a practical, evidence-based tool to facilitate yellow zone guidance in adults.We reviewed recent asthma guidelines and adult studies addressing acute loss of asthma control (January 2010 to March 2016). We developed evidence-based rules for yellow zone therapy and operational guidelines to maximise adherence and minimise

Full Text available with Trip Pro

2017 EvidenceUpdates